| References: |
Description of Ibrutinib (PCI-32765): Ibrutinib is a BTK inhibitor, is also an orally bioavailable small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. BTK inhibitor PCI-32765 binds to and inhibits BTK activity, preventing B-cell activation and B-cell-mediated signaling and inhibiting the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required For B cell receptor (BCR) signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
For the detailed information about the solubility of PCI-32765 (Ibrutinib) in water, the solubility of PCI-32765 (Ibrutinib) in DMSO, the solubility of PCI-32765 (Ibrutinib) in PBS buffer, the animal experiment（test） of PCI-32765 (Ibrutinib),the in vivo,in vitro and clinical trial test of PCI-32765 (Ibrutinib),the cell experiment（test） of PCI-32765 (Ibrutinib),the IC50, EC50 and Affinity of PCI-32765 (Ibrutinib), please contact DC Chemicals. |
